Results for tag: "Biosimilar Therapeutic Peptides"

In the field of biotechnology, the biosimilar therapeutic peptides market comprises a subset of the biosimilar market, which itself is a part of the larger biopharmaceutical industry. Biosimilars are medical products that are nearly identical to an original product manufactured by a different company and are officially approved based on their demonstrated similarity in terms of safety, efficacy, and quality. Therapeutic peptides are short chains of amino acids that possess biological activity and can mimic or influence diverse physiological functions, making them useful for treating a variety of health conditions. Biosimilar therapeutic peptides aim to replicate the clinical effects of their reference biologic peptides but are often available at a lower cost, making them more accessible to patients and healthcare systems. This market involves intricate biotechnological processes and strict regulatory pathways for development and approval. The development of biosimilar peptides involves analyzing and replicating the amino acid sequence of the original product, as well as ensuring that the manufacturing process produces a peptide with a highly similar physical and chemical profile. Additionally, extensive preclinical and clinical trials are required to establish biosimilarity in terms of safety and efficacy. Notable companies involved in the biosimilar therapeutic peptides market include Amgen, which is prominent in the biotechnology industry with a number of biosimilar products, and Novartis' division Sandoz, which is known as a pioneer in the development and commercialization of biosimilars. Other important players include Pfizer, Biocon, and Teva Pharmaceutical Industries, each contributing to Show Less Read more